Introduction
Ceftiofur and cephapirin are cephalosporin class antibiotics currently labeled for use as lactating and dry cow intramammary tubes in the USA. However, when these antibiotics are infused into the mammary quarter they are partially converted to active metabolites. The major metabolite for ceftiofur (CEF) is desfuroylceftiofur (DFC) and for cephapirin (CEPH) the metabolite is deacetylcephapirin (DAC). After the IMM administration of 125 mg of ceftiofur hydrochloride, residue analysis at 12 hrs and 24 hrs showed that 50% and 20% respectively of total residues were from the parent. 1 In a recently published paper that measured residues after the IMM administration of 200mg Cephapirin, the ratio of parent to metabolite was approximately one at 24 hrs post last treatment. 2 These metabolites still have antimicrobial activity, but it was suspected they are not as active as the parent compound when tested against mastitis pathogens.
MIC is the minimum concentration of a particular antibiotic that will inhibit growth of a particular bacterium. A solution of bacteria at a predetermined concentration is cultured from a single isolate and then samples of that solution are tested against a range of dilutions of the test antibiotic. Each dilution change usually represents a doubling of the antibiotic concentration. This testing may be done in tubes containing broth or on agar plates containing the serial antibiotic concentrations. The process is repeated many times for different isolates of the same bacterium and the MIC 50 and MIC 90 are the lowest antibiotic concentrations that will inhibit 50% and 90% respectively of the isolates tested.
Study Design
This study compared the MICs of CEF and CEPH to their respective metabolites DFC and DAC when tested against common mastitis pathogens. Agar dilution MIC methodology was utilized in the study according to Clinical and Laboratory Standards Institute (CSLI) guidelines.
The 488 mastitis isolates tested were all collected on Wisconsin dairy farms from 2005 to 2010. Isolates were from both subclinical and clinical intramammary infections.
With the Staphylococcus aureus, Escherichia coli, and coagulase-negative staphylococci isolates, 12 serial dilutions of the tested antibiotics were used with concentration range being from 0.03 to 64 µg/mL. For the Streptococcus dysgalactiae and Streptococcus uberis isolates, 14 serial dilutions of the tested antibiotics were used with concentration range being from 0.008 to 64µg/mL. Breakpoints for susceptibility and resistance were based on CLSI guidelines and are as follows: There are no guidelines for the metabolites and in the paper the authors assumed the same break points as for the parent antibiotics.
Results
Tables 1 and 2 display a summary of the results of the MIC testing.
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abcd Summary This study demonstrated there can be a significant difference in the MIC between the parent and metabolite of cephalosporin antibiotics for mastitis pathogens. This difference in activity is only really important and relevant when it significantly changes the proportion of isolates that are classified as susceptible to the antibiotic parent compared to its metabolite. Table 1 and Table 2 show the susceptibility to the parent and the metabolite of each mastitis pathogen by clinical or subclinical type.
The breakpoints for the metabolite are assumed to be the same as the parent.
There was a very marked difference in susceptibility of Staph aureus to the parent ceftiofur (100% susceptible) compared to its metabolite desfuroylceftiofur (5.1% susceptible). In contrast 100% of Staph aureus isolates were susceptible to both cephapirin and deacetylcephapirin. Another interesting observation is that there is a 3 (clinical) or 4 (subclinical) dilution difference (8 and 16 times increase in concentration) between the MIC 90 of ceftiofur and desfuroylceftiofur. There was only a one dilution change (doubling in concentration) in the MIC 90 between cephapirin and deacetylcephapirin (both clinical and subclinical).
For the CNS isolates, 97% were susceptible to ceftiofur but only 34.3% were susceptible to its metabolite desfuroylceftiofur. In contrast, 100% of CNS isolates were susceptible to both cephapirin and deacetylcephapirin. There was a 3 dilution difference (8 times increase in concentration) between the MIC 90 of ceftiofur and desfuroylceftiofur. There was only a 1 dilution change (doubling of antibiotic concentration) between the MIC 90 of cephapirin and deacetylcephapirin.
E coli isolates were highly susceptible to both the parent ceftiofur and the metabolite desfuroylceftiofur (95% and 91% respectively). There was a marked difference between the parent cephapirin (51% susceptibility) and the metabolite deacetylcephapirin where no isolates were sensitive at the highest concentration tested. There was a single dilution difference (doubling in antibiotic concentration) between the MIC 90 of ceftiofur and desfuroylceftiofur. The MIC 90 of deacetylcephapirin could not be determined because it was beyond the highest antibiotic concentration tested (64 µg/mL). The MIC results from this study clearly demonstrate the 1 st generation cephalosporins are more effective in vitro against Gram positive pathogens, whereas the 3 rd generation cephalosporins have superior Gram negative activity. It is also interesting to note that where cephapirin and deacetylcephapirin had superior activity (gram positive pathogens) there was only a 1 dilution difference between their MIC 90 and where ceftiofur and desfuroylceftiofur had superior activity (E coli) there was also only a 1 dilution difference in their MIC 90 .
There was a very large difference in the MIC 90 for ceftiofur and desfuroyl ceftiofur for Staph aureus and the coagulase negative staphylocci which could become a concern with therapy. The Strep spp tested were highly susceptible to parent and metabolite for both ceftiofur and cephapirin.
The efficacy of intramammary therapy for a particular pathogen may depend on how much of the parent antibiotic has been metabolized. Routine laboratory susceptibility testing only reports MIC results for the parent compound. Several papers cited by the authors of this paper have commented on the lack of correlation between MIC results and clinical outcome in the treatment of mastitis. These results strongly suggest the MIC difference between parent and metabolite may be a very important factor responsible for this lack of correlation. The most appropriate antibiotic for intramammary therapy is likely to be dependent on the proportion of parent-to-metabolite in the udder and the ramifications of the MIC change between the two. 
Statistical analysis:
Survival analysis was used to determine whether the metabolites DFC and DAC had different MICs compared with the MICs of the parent compounds (CEF and CEPH respectively). Log rank and Wilcoxin tests were employed and values of P < 0.05 were considered significant.
A summary of the results for each mastitis pathogen tested is given on the following page. There was a one dilution difference between the MIC 90 of CEF and DFC (SCI).
The % of S dysgalactiae sensitive to CEPH was 100%.
The % of S dysgalactiae sensitive to DAC was 100%.
There was a two dilution change (CIs & SCIs) between the MIC 90 of CEPH and DAC.
Heterogenous survival curves were obtained between CEPH and DAC (CIs & SCIs) (P < .001; log-rank and Wilcoxon tests).
Survival curves for CEF and DFC (CIs & SCIs) were homogenous (no significant statistical difference).
S uberis: (48 Clinical, 48 Subclinical isolates tested)
The lowest MIC 90 was for CEPH at 0.5 µg/mL (CI & SCI).
The highest MIC 90 was for CEF & DFC (SCI) at 2 µg/mL.
The % of S uberis sensitive to CEF was 94%.
The % of S uberis sensitive to DFC was 92%.
There was a no dilution (CIs & SCIs) difference between the MIC 90 of CEF and DFC.
The % of S uberis sensitive to CEPH was 100%.
The % of S uberis sensitive to DAC was 100% (MIC 90 1.0 µg/mL).
There was a one dilution difference (CIs & SCIs) between the MIC 90 of CEPH and DAC.
